Selective iGluR5 receptor antagonists for the treatment of neurological disorders
AssigneeEli Lilly and Company
InventorsSandra Ann Filla, Paul Leslie Ornstein
Life of this patent
Estimating the term…
Abstract
The present invention provides a method of treating or preventing migraine comprising administering to a patient in need thereof an effective amount of a selective iGluR5 receptor antagonist. The present mvention further provides novel compounds functional as selective iGluR5 receptor antagonists as well as compositions and s cspng said selective iGluR5 receptor antagonists.
Claims20
A method of treating migraine comprising administering to a patient in need thereof an effective amount of a selective iGluR5 receptor antagonist or a pharmaceutically acceptable salt thereof.
A method of treating migraine comprising administering to a patient in need thereof a pharmaceutical composition comprising a selective iGiuR5 receptor antagonist in combinationwith one or more pharmaceutically acceptable carmers, diluents, or excipients.
A method of treating dural protein extravasation comprising administering to a patient in need thereof an effective amount of a selective iGluR5 receptor antagonist.
A method of treating migraine comprising administering to a patient in need thereof an effective amount of a compound, or combination thereof, which possesses the activity of a selective iGluR5 receptor antagonist.
The use of a selective iGluR5 receptor antagonist for the manufacture of a medicament for treating migraine.
A compound of the formula
- 16
- wherein R1 and R2 are each independently H, C1-C20 alkyl, C2-C6 alkenyl, C1-C6 alkylaryl, C1-C6 alkyl(C3-C10)cycloalkyl, C1-C6 alkyl-N,N-C1-C6 dialkylamine, C1-C6 alkyl-pyrrolidine, C1-C6 alkyl-piperidine, C1-C6 alkyl-morpholine or a pharmaceutically accepatable salt thereof.
A compound which is 3S, 4aR, 6S, 8aR Ethyl 6-(((2S)-2-(Ethoxycarbonyl)-4,4-difluoropyrrolidinyl)methyl)-1, 2, 3, 4, 4a, 5, 6, 7, 8, 8a-decahydroisoquinoline-3-carboxylate, or a pharmaceutically acceptable salt thereof.
A compound which is 3S, 4aR, 6S, 8aR 6-(((2S)-2-(Carboxylic acid)-4,4-difluoropyrrolidinyl)methyl)-1, 2, 3, 4, 4a, 5, 6, 7, 8, 8a-decahydroisoquinollne-3-carboxylic acid, or a pharmaceutically acceptable salt thereof.
A pharmaceutical composition for the treatment of migraine which comprises a selective iGluR5 receptor antagonist in combination with a pharmaceutically acceptable carrier, diluent, or excipient.
A compound which is 3S, 4aR, 6S, 8aR Ethyl 6-(((2S)2-(Ethoxycarbonyl)-4,4-difluoropyrrolidinyl)methyl)-1, 2, 3, 4, 4a, 5, 6, 7, 8, 8a-decahydroisoquinoline-3-carboxylate•mandelate.
Dependencies are inferred from the claim text.